FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3137785626> ?p ?o ?g. }

• W3137785626 endingPage "427" @default.
• W3137785626 startingPage "427" @default.
• W3137785626 abstract "Non-small cell lung cancer (NSCLC) is a typical inflammation-associated cancer, and lung adenocarcinoma (LUAD) is the most common histopathological subtype. Epidermal growth factor receptor (EGFR) mutations are the most common driver mutations of LUAD, and they have been identified as important therapeutic targets by EGFR tyrosine kinase inhibitors. Interleukin (IL)-17A secreted by T-helper 17 lymphocytes is a proinflammatory cytokine that plays an important role in cancer pathogenesis. The present study was designed to investigate the possible associations among IL-17A genetic polymorphisms, EGFR mutation status, and the clinicopathologic development of LUAD in a Taiwanese population. Our study population consisted of 277 LUAD patients harboring the wild-type (WT) EGFR or a mutant (MT) EGFR. Four single-nucleotide polymorphisms (SNPs) of IL-17A in the peripheral blood, including rs8193036(C > T), rs8193037(G > A), rs2275913(G > A), and rs3748067(C > T) loci, were genotyped using a TaqMan allelic discrimination assay. Our results showed that none of these IL-17A SNPs were correlated with the risk of developing mutant EGFR. However, patients with a smoking habit who carried the GA genotype of IL-17A rs8193037 had a significantly lower susceptibility to EGFR mutations (adjusted odds ratio (AOR): 0.225; 95% confidence interval (CI): 0.056~0.900, p = 0.035). Moreover, compared to individuals carrying the CC genotype of rs8193036 at IL-17A, T-allele carriers (CT + TT) were at higher risk of developing more-advanced stages (stage III or IV; p = 0.020). In the WT EGFR subgroup analysis, IL-17A rs8193036 T-allele carriers had higher risks of developing an advanced tumor stage (p = 0.016) and lymphatic invasion (p = 0.049). Further analyses of clinical datasets revealed correlations of IL-17 receptor A (IL-17RA) and IL-17RC expressions with a poor prognosis of LUAD patients with a smoking history or with higher levels of tumor-infiltrating lymphocytes. In conclusion, our results suggested that two functional promoter polymorphisms of IL-17A, i.e., rs8193036 and rs8193037, were associated with the EGFR mutation status and progression in LUAD patients, indicating that these two genetic variants might act as possible markers for predicting patients’ clinical prognoses." @default.
• W3137785626 created "2021-03-29" @default.
• W3137785626 creator A5015211581 @default.
• W3137785626 creator A5022463247 @default.
• W3137785626 creator A5031594831 @default.
• W3137785626 creator A5041510877 @default.
• W3137785626 creator A5058805243 @default.
• W3137785626 creator A5059148873 @default.
• W3137785626 creator A5062664426 @default.
• W3137785626 creator A5070435565 @default.
• W3137785626 creator A5076879172 @default.
• W3137785626 creator A5086997790 @default.
• W3137785626 creator A5090171067 @default.
• W3137785626 date "2021-03-17" @default.
• W3137785626 modified "2023-10-16" @default.
• W3137785626 title "Potential Impacts of Interleukin-17A Promoter Polymorphisms on the EGFR Mutation Status and Progression of Non-Small Cell Lung Cancer in Taiwan" @default.
• W3137785626 cites W1456869083 @default.
• W3137785626 cites W1997828131 @default.
• W3137785626 cites W2005312471 @default.
• W3137785626 cites W2006145996 @default.
• W3137785626 cites W2011445291 @default.
• W3137785626 cites W2050565829 @default.
• W3137785626 cites W2061833582 @default.
• W3137785626 cites W2075040668 @default.
• W3137785626 cites W2075344814 @default.
• W3137785626 cites W2089157658 @default.
• W3137785626 cites W2089381299 @default.
• W3137785626 cites W2098395191 @default.
• W3137785626 cites W2111662961 @default.
• W3137785626 cites W2116510568 @default.
• W3137785626 cites W2123105952 @default.
• W3137785626 cites W2127897870 @default.
• W3137785626 cites W2143859186 @default.
• W3137785626 cites W2159469480 @default.
• W3137785626 cites W2166084034 @default.
• W3137785626 cites W2171139285 @default.
• W3137785626 cites W2172208170 @default.
• W3137785626 cites W2256155471 @default.
• W3137785626 cites W2269729332 @default.
• W3137785626 cites W2485259790 @default.
• W3137785626 cites W2517512205 @default.
• W3137785626 cites W2544207313 @default.
• W3137785626 cites W2610919492 @default.
• W3137785626 cites W2765142182 @default.
• W3137785626 cites W2894674103 @default.
• W3137785626 cites W2904970316 @default.
• W3137785626 cites W2905823481 @default.
• W3137785626 cites W2910383224 @default.
• W3137785626 cites W2949999931 @default.
• W3137785626 cites W2988046914 @default.
• W3137785626 cites W2988328495 @default.
• W3137785626 cites W2999417355 @default.
• W3137785626 cites W3004892587 @default.
• W3137785626 cites W52192959 @default.
• W3137785626 doi "https://doi.org/10.3390/genes12030427" @default.
• W3137785626 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8002550" @default.
• W3137785626 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33802737" @default.
• W3137785626 hasPublicationYear "2021" @default.
• W3137785626 type Work @default.
• W3137785626 sameAs 3137785626 @default.
• W3137785626 citedByCount "3" @default.
• W3137785626 countsByYear W31377856262021 @default.
• W3137785626 countsByYear W31377856262022 @default.
• W3137785626 countsByYear W31377856262023 @default.
• W3137785626 crossrefType "journal-article" @default.
• W3137785626 hasAuthorship W3137785626A5015211581 @default.
• W3137785626 hasAuthorship W3137785626A5022463247 @default.
• W3137785626 hasAuthorship W3137785626A5031594831 @default.
• W3137785626 hasAuthorship W3137785626A5041510877 @default.
• W3137785626 hasAuthorship W3137785626A5058805243 @default.
• W3137785626 hasAuthorship W3137785626A5059148873 @default.
• W3137785626 hasAuthorship W3137785626A5062664426 @default.
• W3137785626 hasAuthorship W3137785626A5070435565 @default.
• W3137785626 hasAuthorship W3137785626A5076879172 @default.
• W3137785626 hasAuthorship W3137785626A5086997790 @default.
• W3137785626 hasAuthorship W3137785626A5090171067 @default.
• W3137785626 hasBestOaLocation W31377856261 @default.
• W3137785626 hasConcept C104317684 @default.
• W3137785626 hasConcept C121608353 @default.
• W3137785626 hasConcept C126322002 @default.
• W3137785626 hasConcept C135763542 @default.
• W3137785626 hasConcept C143998085 @default.
• W3137785626 hasConcept C153209595 @default.
• W3137785626 hasConcept C156957248 @default.
• W3137785626 hasConcept C180754005 @default.
• W3137785626 hasConcept C203014093 @default.
• W3137785626 hasConcept C2776256026 @default.
• W3137785626 hasConcept C2779438470 @default.
• W3137785626 hasConcept C2781182431 @default.
• W3137785626 hasConcept C2908647359 @default.
• W3137785626 hasConcept C502942594 @default.
• W3137785626 hasConcept C54355233 @default.
• W3137785626 hasConcept C71924100 @default.
• W3137785626 hasConcept C86803240 @default.
• W3137785626 hasConcept C99454951 @default.
• W3137785626 hasConceptScore W3137785626C104317684 @default.
• W3137785626 hasConceptScore W3137785626C121608353 @default.
• W3137785626 hasConceptScore W3137785626C126322002 @default.

• next